FDA Approves Tremfya for Ulcerative Colitis
The FDA has approved Johnson & Johnson’s supplemental application for Tremfya (guselkumab) to treat adults with moderately to severely active ulcerative colitis (UC). Tremfya is fully-human, dual-acting monoclonal antibody that blocks IL-23 while also …